Dementia
NASEM found limited evidence that cannabinoids are INEFFECTIVE for dementia symptoms.
What the evidence says
NASEM 2017: limited evidence that cannabinoids are INEFFECTIVE for improving symptoms associated with dementia.
NASEM concluded there is limited evidence that cannabinoids are ineffective for improving symptoms associated with dementia.
A 2024 systematic review separately reported no evidence of neuroprotective or anti-aggregatory effects of alpha-pinene or beta-pinene against beta-amyloid-mediated toxicity — one of the specific mechanisms sometimes invoked in marketing.
Older adults are also more susceptible to cognitive side effects and falls. This is a population where caution is warranted.
We do not recommend cannabis for this
Rather than suggest a product profile, we are telling you the evidence points the other way. Talk to a clinician about options with better support.
Talk to a doctor if
- • You are caring for someone with dementia and considering cannabis — involve their physician
- • There is new or rapid cognitive change
Related conditions
- Multiple sclerosis spasticityMuscle stiffness and spasm in multiple sclerosis. Substantial evidence for patient-reported improvement; weaker for clinician-measured.
- Tourette syndromeTic disorder. Limited evidence for THC capsules.
- Epilepsy and seizure disordersPrescription CBD has strong RCT evidence in three specific syndromes. Dispensary products do not.
- ADHDAttention-deficit/hyperactivity disorder. No supporting evidence, and acute cannabis use impairs attention.
Sources
- NASEM 2017, Committee Conclusions (summary PDF of all evidence-tier conclusions).Accessed 2026-08-15.
- André R, Gomes AP, Pereira-Leite C, et al. The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review. Pharmaceuticals. 2024;17(11):1543.(DOI 10.3390/ph17111543)Accessed 2026-08-15.